European collaboration agreement in dermatology

European collaboration agreement in dermatology 

Meda has entered into an agreement with Uluru Inc, a US specialty pharma
company, for Amlexanox 5% paste and OraDisc A™. The agreement gives Meda
exclusive rights to the products in most European countries, including Eastern
Europe. 

Both products are used for the treatment of canker sores and include the active
ingredient amlexanox. OraDisc A™ is a novel patented mucoadhesive,
water-erodible disc incorporating 2mg of amlexanox for the treatment and
prevention of aphthous ulcers. The disc is applied to the sore and adheres to
the mouth mucosa and the active ingredient is released locally. 

Meda will pay an up-front of about EUR 0,5 million for these rights. Total
milestone payments are below EUR 4,8 million. 

“OraDisc is a unique product that fits our product portfolio in Europe. A
specialist sales force is already established and we hope to be able to launch
the product already during 2010”, said Anders Lönner, CEO Meda. 




For more information, please contact:

Anders Larnholt, Vice President Investor Relations, tel. +46 709 458 878


MEDA AB (publ) is a leading international specialty pharma company. The company
specialises in marketing and pharmaceutical development in late clinical stage.
Acquisitions and long-term partnerships are fundamental factors that drive the
company's strategy. Meda is represented by its own organisations in about 40
countries. Meda's products are sold in 120 countries worldwide. The Meda share
is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit
www.meda.se.